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Table. Number of virus detections, average PCR CT values, and sensitivity of PCR for detection in wet versus dry swab collections
Negative
Swab Pairs
Virus
Detections:
Positive
Wet & Dry
Virus
Detections:
Positive Wet,
Negative Dry
Virus
Detections:
Positive Dry,
Negative Wet % Sensitivity
N N (Ave. CT Value Wet; Dry) N (Ave. CT Value) N (Ave. CT Value) Wet Swabs Dry Swabs
Immunocompetent Controls (N 5 106
collections)
All virus detections# 28 78 (27.1; 27.2) 10 (34.6) 3 (34.3) 97 89
+ Rhinorrhea (n 5 83)* 18 65 (26.8; 26.8) 7a (35.4) 3b (34.3) 96 91
2 Rhinorrhea (n 5 22)* 9 13 (28.9; 29.4) 3c (32.8) 0 100 81
HCT Patients (N 5 105 collections)
All virus detections# 20 69 (28.2; 28.4) 14 (33.5) 12 (32.8) 87 85
+ Rhinorrhea (n 5 66) 9 48 (27.5; 27.8) 8d (32.5) 7e (33.0) 89 87
2 Rhinorrhea (n 5 39) 11 21 (29.9; 29.7) 6f (35.9) 5g (32.4) 84 81
#Total N is greater than number of paired swab collections because of multiple virus detections in some swabs.
*1 survey was blank for rhinorrhea and omitted. Discordant virus detections.
aAdenovirus (AdV) x3, parainfluenza (PIV) 3, PIV4, coronavirus (HCoV)/rhinovirus (HRV) co-infection.
bHRV x2, bocavirus.
cInfluenza A, AdV, HCoV.
drespiratory syncytial virus (RSV) x2, PIV3 x2, HRV x2, AdV, HCoV.
ePIV3, PIV1, HCoV, HRV x4.
fRSV, PIV3 x2, HCoV x2, AdV.
gRSV x2, HRV x3.
S346 Poster Session IIwere stored at ambient temperature, and PCR testing was performed
for 12 RVs (positive value 5 threshold cycle [CT]\ 40).
Results: Samples were collected during 106 URIs in 70 immuno-
competent persons; 3 subjects were \ 6 yo (parent performed).
Counting all positive respiratory virus detections as true positives,
sensitivity was 88/91 5 97% for wet swabs and 81/91 5 91% for
dry (Table). Among 30 HCT recipients aged . 6 yo, 105 paired
samples were collected during 30 URIs (median 3 samples/patient,
range 1-9). Sensitivity was 83/955 87% for wet swabs and 81/955
85% for dry. In both populations, discordant results were associated
with higher averageCT values (i.e., lower viral load), and discordance
was highest in samples collected fromHCT recipients. Dry swabs, in
particular, appeared to perform better in subjects with rhinorrhea
than without. A subset of 73 immunocompetent subjects rated the
self collected swabs simple (96%) and comfortable (88%); no epi-
staxis occurred with any collection.
Conclusion: Ourmethod of foam swab self-collection of nasal secre-
tions is simple, comfortable, and safe amongHCT recipients. Discor-
dance between wet and dry swabs increased with lower viral load.
Overall, thewet swabappeared to increase sensitivity for respiratory vi-
ral detection in both immunocompetent subjects and HCT patients.
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ALLOGENEIC STEM CELL TRANSPLANTATION FOR SICKLE CELL ANEMIA
(SCA) AT MSKCC: A SINGLE INSTITUTION SERIES
Anur, P., Sklar, C., Kernan, N.A., Prockop, S.E., Scaradavou, A.,
Small, T.N., O’Reilly, R.J., Boulad, F. Memorial Sloan Kettering Cancer
Center, New York, NY
Background: Allogeneic hematopoietic stem cell transplantation
(SCT) is the only proven cure for children with sickle cell anemia.
SCT is considered for high risk patients with SCA who have an
HLA-matched sibling donor.
Methods: We reviewed medical records of 13 children (1.4 -19.2
years, 8 females and 5 males) who received allogeneic SCT from
matched sibling donors from 1994-2010 for SCA at Memorial
Sloan-Kettering Cancer Center (MSKCC).
Results: Indications for HSCTwere: stroke (n5 3), acute chest syn-
drome (n 5 6), multiple vaso-occlusive crises (n 5 10), and allo-im-
munization (n 5 3); nine patients had more than one risk factor.
Donors were heterozygous for sickle cell (n5 9) or with normal he-
moglobin (n 5 4). All patients received marrow grafts while one pa-
tient received combined marrow and cord blood grafts. Nine
patients received standard cytoreduction with Busulfan/Cyclophos-
phamide. Three other regimens were used in an attempt to decrease
toxicity and improve chimerism. They were Busulfan/Fludarabine
(n 5 2), Busulfan/Cyclophosphamide/Fludarabine (n 5 1) andBusulfan/Melphalan/Fludarabine (n 5 1). GvHD prophylaxis in-
cluded cyclosporine (CSA) and methotrexate (MTX) (n 5 9), tacro-
limus and MTX (n 5 2), or other (n 5 2). All 13 patients engrafted.
With a median follow-up of 10.2 years (range 0.9-17.6 years), twelve
of 13 patients are alive and well. One patient died of interstitial pneu-
monitis on day +77 post SCT. No patient developed acute GvHD.
Two patients developed de-novo limited chronic GvHD, which re-
solved. Donor chimerism included 100% (n 5 5), 76-97% (n 5 5)
while two patients recipients of Bu/Cy regimen had 35% and 50%
donor cells. Six of 7 evaluable patients showed evidence of splenic
function recovery post transplant. Late effects analysis included eval-
uation of gonadal function revealing 6 of 8 females with ovarian
dysfunction.
Conclusions: This single institution based SCT series for SCA is
consistent with multi-institutional series results, showing a very
good outcome following Busulfan based myeloablative regimen. Fu-
ture directions include the improvement of donor chimerism, and
the late effects of treatment including that of gonadal function.
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FAVORABLE OUTCOMES IN ELDERLY AND HIGH-RISK PATIENTS WITH
AML AND MDS FOLLOWING T-CELL DEPLETED REDUCED INTENSITY
CONDITIONED ALLOGENEIC STEM CELL TRANSPLANTATION
Nicholson, E.1, Mackinnon, S.1, Thomson, K.J.2, Sudak, J.1,
Fielding, A.K.1, Kottaridis, P.1, Peggs, K.S.2, Morris, E.C.2,
Chakraverty, R.1 1Royal Free Hospital, London, United Kingdom;
2University College Hospital, London, United Kingdom
For patients with high-risk acute myeloid leukemia(AML),mye-
loablative conditioning(MAC) followed by allogeneic hematopoietic
stem cell transplantation(allo-HSCT) offers the best chance of long-
term disease free survival.Retrospective analysis comparing reduced
intensity conditioning(RIC) and MAC suggest that early OS and
PFS rates are comparable where increased relapse rate(RR) is offset
by reduced non-relapse mortality(NRM).In AML patients receiving
a RIC regimen,very high RR has been observed in patients with poor
risk cytogenetics.We analyzed outcomes of 70 consecutive adult pa-
tients with AML or MDS(CR1 or CR2 at time of allo-HSCT) who
received Fludarabine(150mg/m2),Melphalan(140mg/m2) Alemtu-
zumab(CAMPATH)(20-100mg)(FMC) RIC regimen.Median age
at transplant was 56 yrs(range 17-70).29 had a HLA identical sibling
donor and 41 an unrelated donor(29 matched;12 mismatched).Stem
cell source was PBSC in 66 and BM in 4 patients.43 patients were in
CR1 and 27 were in CR2.Median follow up of live patients was 32
months(range 12-119).OS and PFS at 3 yrs was 55% and
53%.100-day and 3-yr NRM rates were 10% and 24%.3-yr
RR was 25% and median time to relapse was 6.2 months (range
Poster Session II S3472 - 41).The cumulative incidence(CI) of severe acute GvHD(grade
II-IV) was 7% at 100 days.3-yr CI of chronic GvHD was 25%.3-
yr OS and PFS was 69% and 66% for sibling vs 42%(p 5 0.08)
and 41%(p 5 0.14) for unrelated donors.3-yr NRM and RR was
14% and 25% for sibling vs 31%(p 5 0.15) and 28%(p 5 0.27) for
unrelated donors.Outcomes for patients who had high-risk(HR) fea-
tures prior to transplant(poor risk cytogenetics,FLT3 ITD muta-
tion,previous MDS,secondary AML) were compared to outcomes
of those with standard risk(SR) disease.The HR group(n 5 37) had
OS and PFS at 3 yrs of 50% and 47% vs 60%(p 5 0.13) and
60%(p 5 0.1) for SR group(n 5 33).3-yr NRM and RR was 21%
and 25% in the HR group vs 23%(p 5 0.19) and 24%(p 5 0.18)
in the SR group(p 5 0.19).The 23 patients $60 yrs(20 unrelated
and/or HR) had a 3 yr OS of 38% and PFS of 38%. In conclusion,
many patients withHRAMLwho attain CRmaintain durable remis-
sions following RIC allo-HSCT with the FMC regimen. Although
outcomes are marginally less good than seen in patients with SR
AML receiving RIC transplant, they are much better than would
be achieved with current chemotherapy regimens.The low NRM
in sibling allo-HSCT together with the relatively low RR support
further exploration of FMC conditioned allo-HSCT in all patients
with SR AML with a matched sibling donor.
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PRACTICE VARIATION IN PHYSICIAN REFERRAL FOR ALLOGENEIC HE-
MATOPOIETIC CELL TRANSPLANTATION
Pidala, J.1, Craig, B.2, Lee, S.J.3, Majhail, N.4, Quinn, G.2, Anasetti, C.1
1Moffitt Cancer Center, Tampa, FL; 2Moffitt Cancer Center; 3Fred
Hutchinson Cancer Research Center; 4University of Minnesota
Hematologic malignancy patients who are not referred by their
primary Hematologist or Medical Oncologist suffer disparate access
to allogeneic hematopoietic cell transplantation (HCT). However,
systematic investigation into physician, system, and patient factors
relevant to this decision making is lacking. Accordingly, we surveyed
a nationally representative random sample of practicing Hematolo-
gists/Medical Oncologists identified through the AMA Masterfile.
The survey content was organized in three sections: (I) Vignette
based decision making according to best-worst scaling; (II) examina-
tion of physician, system and patient factors relevant to decision
making; and (III) respondent socio-demographic information. A
modified Dillman approach was utilized to encourage survey re-
sponse rate. From 1,200 surveyed, a total of 113 physicians
responded. Of these, 68% were male, 62% identified as White/
non-Hispanic, 79% practiced in non-academic settings, and 80% re-
ported spending 75-100% of their professional effort in clinical care.
From best-worst scaling data provided by physicians in response to
clinical vignettes, we detected significantly increased odds for non-
HCT referral according to age (age 60 vs. 30, OR 8.3, 95% CI
5.9-11.7, p\ 0.0001), race (African American vs. Caucasian, OR
2.4, 95%CI 1.9-2.9, p\0.0001), and insurance coverage (no cover-
age vs. coverage, OR 6.9, 95%CI 5.2-9.1, p\ 0.0001). Four attri-
bute-specific Wald tests reject equivalence in odds ratios across the
four diseases (MDS, ALL, CML, AML) at a p-value less than 0.05,
indicating condition-specific variability. Physician (perception of
HCT risks), system (insurance coverage), and patient (age, social
support, co-morbid illness) factors were strongly endorsed by re-
spondents as important determinants of their HCT referral prac-
tices. The majority (64%) of physicians indicated that patients do
not have equal access to HCT consultation. Qualitative comments
provided even greater clarity to perceived barriers to HCT referral,
largely focused on lack of insurance coverage and need for increased
education of practicing Hematologists/Medical Oncologists on tim-
ing and indication for HCT referral. These data speak to important
factors relevant to HCT referral practices, and highlight several op-
portunities for education and intervention to reduce current dispar-
ities in access to HCT.
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ALLOGENEIC STEM CELL TRANSPLANTATION IN SECONDARY ACUTEMY-
ELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME: OHSU EXPERI-
ENCE
Perets Avraham, G.1, Meyers, G.1, Kovacsovics, T.1, Curtin, P.T.2,
Leis, J.F.3, Bains, T.1, Lemieux, A.1, Maziarz, R.T.1 1Oregon Healthand Science University, Portland, OR; 2UC San Diego, La Jolla, CA;
3Mayo clinic College of Medicine, Scottsdale, AZ
Therapy related acute myeloid leukemia (t-AML) and myelodys-
plastic syndrome (t-MDS) have poor outcomes with conventional
chemotherapy. The only curative treatment is allogeneic hematopoi-
etic cell transplantation (HCT). Secondary AML evolving from
MDS (s-AML) has a similar poor prognosis with conventional anti-
leukemia therapies.
In this retrospective study, the transplant outcomes of 91 adult pa-
tients with t-AML (n 5 19), t-MDS (n 5 19) and s-AML (n 5 53)
treated with allogeneic HCT at OHSU from January 1997 to De-
cember 2010 were assessed.
Themedian age of patientswas 55 years (range: 21-72).Median age
for t-AML, t-MDS, and s-AMLwas 51, 59, and 56 years, respectively.
Poor risk cytogenetics were found in 18% of t-MDS pts and 38% of
the AML pts. Donors were mostly matched unrelated (61%), and
a myeloablative regimen was used for conditioning in 68% of the pa-
tients. Two-yearoverall survival (OS) and relapse incidencewere 44%
and 43%, respectively, for all cohorts. NRMwas 13% at 100 days and
33% at 2 years. s-AML patients had significantly improved OS com-
pared to t-AML and t-MDS patients (HR5 0.5, p5 0.02).
Four adverse risk factors impact on DFS and OS in t-AML/MDS
pts (Litzow, Blood 2010). Outcomes in our s-AML patients were as-
sessed for these factors: age . 35 years; poor-risk cytogenetics; t-
AML not in remission or advanced t-MDS; and donor other than
an HLA-identical sibling or a partially or well-matched unrelated
donor. One-year event-free survival for our subjects with 0-1, 2, or
3-4 of these risk factors was 83%, 63%, and 34%, respectively
(p5 0.01), but OS was not different (p5 0.28). However, pre-trans-
plant KPS # 80; intermediate or poor cytogenetics; and URD mis-
matched or other relative donor impacted with one-year OS for
subjects with 1, 2, or 3 of these risk factors 5 62%, 24%, and
33%, respectively (p 5 0.04).
In conclusion, the CIBMTR scoring system for t-AML/MDS was
not fully validated in our t-MDS, t-AML, and s-AML patients, but
appeared overall consistent.
However, performance status, rather than age, was more predic-
tive for OS.
Also, s-AML had improved OS compared to t-AML and t-MDS
patients, suggesting that these are biologically different diseases.
These data also indicate the need for the identification of prognos-
tic factors for secondary AML/MDS patients, to permit accurate
prediction of allogeneic HCT outcomes in this unique patient
population.
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IMPROVED OUTCOME OF ELDERLY PATIENTS AFTER REDUCED INTEN-
SITY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Perets Avraham, G.1, Bains, T.1, Lemieux, A.1, Slater, S.1,
Kovacsovics, T.1, Curtin, P.2, Gajewski, J.1, Meyers, G.1,
Maziarz, R.T.1 1Knight Cancer Institute, Oregon Health and Science
University, Portland, OR; 2UCSD Moores Cancer Center, La Jolla, CA
Advanced age has been associated with higher mortality after mye-
loablative (MA) allogeneic hematopoietic cell transplantation
(HCT). Reduced intensity conditioning (RIC) and non myeloabla-
tive (NM) regimens have been developed to expand allogeneic
HCT to the aging population. A retrospective analysis of patients
aged 60 and older was performed and outcome of patients trans-
planted with MA, RIC and NM regimens were assessed.
159 patients transplanted between January 1998 and December
2010 for hematological malignancies were analyzed. 41 patients un-
derwent MA, 100 patients underwent RIC and 18 patients under-
went NM conditioned HCT. 62 patients (39%) had a matched
related donor, 67 (42%) had a matched unrelated donor and 30
(19%) had a mismatch donor HCT.
Overall survival (OS) was significantly influenced by conditioning
regimen (p 5 0.03). One year OS was 59%, 30% and 28% for RIC,
NM and MA group respectively. 3 year OS was significantly better
for RIC at 26% vs. 15% for MA (p5 0.02). There was no significant
difference in the progression free survival (PFS) and relapse rate be-
tween the three groups. There was trend towards significance for
non relapse mortality (NRM) based on conditioning regimen (p 5
0.07) and 100 day NRM was 11%, 3.5% and 6% for MA, RIC and
NM respectively.
